[go: up one dir, main page]

NO20015003L - Nucleic Acids Encoding CD40 / CD40L Chimeric Polypeptides, Methods of Preparation and Use thereof - Google Patents

Nucleic Acids Encoding CD40 / CD40L Chimeric Polypeptides, Methods of Preparation and Use thereof

Info

Publication number
NO20015003L
NO20015003L NO20015003A NO20015003A NO20015003L NO 20015003 L NO20015003 L NO 20015003L NO 20015003 A NO20015003 A NO 20015003A NO 20015003 A NO20015003 A NO 20015003A NO 20015003 L NO20015003 L NO 20015003L
Authority
NO
Norway
Prior art keywords
preparation
methods
nucleic acids
acids encoding
chimeric polypeptides
Prior art date
Application number
NO20015003A
Other languages
Norwegian (no)
Other versions
NO20015003D0 (en
Inventor
Frank Dicker
Thomas Friess
Gerd Maass
Ulrich Pessara
Werner Scheuer
Stefan Seeber
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP99107611A external-priority patent/EP1067194A1/en
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of NO20015003L publication Critical patent/NO20015003L/en
Publication of NO20015003D0 publication Critical patent/NO20015003D0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
NO20015003A 1999-04-16 2001-10-15 Nucleic Acids Encoding CD40 / CD40L Chimeric Polypeptides, Methods of Preparation and Use thereof NO20015003D0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP99107611A EP1067194A1 (en) 1999-04-16 1999-04-16 Vectors containing a gene coding for CD40 and/or CD40L under the control of a cytokine-inducible promoter which is a human acute phase amyloid A gene promoter. Methods for their production and uses thereof
EP99113967 1999-07-17
PCT/EP2000/003318 WO2000063395A1 (en) 1999-04-16 2000-04-13 Nucleic acids encoding cd40/cd40l chimeric polypeptides, methods for their production and uses thereof

Publications (2)

Publication Number Publication Date
NO20015003L true NO20015003L (en) 2001-10-15
NO20015003D0 NO20015003D0 (en) 2001-10-15

Family

ID=26152970

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20015003A NO20015003D0 (en) 1999-04-16 2001-10-15 Nucleic Acids Encoding CD40 / CD40L Chimeric Polypeptides, Methods of Preparation and Use thereof

Country Status (8)

Country Link
EP (1) EP1173589A1 (en)
JP (1) JP2003508016A (en)
AR (1) AR023482A1 (en)
AU (1) AU3966200A (en)
CA (1) CA2369820A1 (en)
IL (1) IL144952A0 (en)
NO (1) NO20015003D0 (en)
WO (1) WO2000063395A1 (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2424749A1 (en) 2000-10-02 2002-04-11 Chiron Corporation Methods of therapy for b-cell malignancies using antagonist anti-cd40 antibodies
AU2002221780A1 (en) * 2000-10-31 2002-05-15 F.Hoffmann-La Roche Ag Nucleic acids encoding cd40/cd40l chimeric polypeptides, methods for their production and uses thereof
ATE476991T1 (en) 2003-11-04 2010-08-15 Novartis Vaccines & Diagnostic METHOD FOR TREATING SOLID TUMORS WITH EXPRESSION OF CD40 CELL SURFACE ANTIGEN
EP2248830A1 (en) 2003-11-04 2010-11-10 Novartis Vaccines and Diagnostics, Inc. Use of antagonist anti-CD40 antibodies for treatment of autoimmune and inflammatory diseases and organ transplant rejection
WO2005044855A2 (en) 2003-11-04 2005-05-19 Chiron Corporation Use of antagonist anti-cd40 monoclonal antibodies for treatment of multiple myeloma
EP2236172A1 (en) 2003-11-04 2010-10-06 Novartis Vaccines and Diagnostics, Inc. Combination therapy comprising anti-CD20 and anti-CD40 antibodies for the treatment of B cell-related cancers
US20070110754A1 (en) 2003-11-04 2007-05-17 Chiron Corporation Use of antagonist anti-cd40 antibodies for treatment of chronic lymphocytic leukemia
EP2312315A1 (en) 2005-05-18 2011-04-20 Novartis AG Methods for diagnosis and treatment of diseases having an autoimmune and/or inflammatory component
AR060487A1 (en) 2006-04-21 2008-06-18 Xoma Technology Ltd PHARMACEUTICAL COMPOSITIONS OF ANTI-BODY ANTAGONISTS ANTI-CD40
ES2520026T3 (en) 2006-09-18 2014-11-11 The Board Of Trustees Of The University Of Arkansas Compositions and methods to boost immune responses
CN102037135A (en) 2007-10-30 2011-04-27 阿肯色大学评议会 Compositions and methods for enhancing immune responses to flagellated bacteria
AU2008318357B2 (en) 2007-11-01 2015-01-22 The Board Of Trustees Of The University Of Arkansas Compositions and methods of enhancing immune responses to eimeria
JP5568807B2 (en) * 2008-06-06 2014-08-13 静岡県 Identification of melanoma markers using proteomic analysis
AU2011207331C1 (en) 2010-01-21 2016-05-12 The Texas A&M University System Vaccine vectors and methods of enhancing immune responses
KR101881611B1 (en) 2010-06-09 2018-07-25 더 보드 오브 트러스티스 오브 더 유니버시티 오브 아칸소 Vaccine and methods to reduce campylobacter infection
WO2012075111A1 (en) 2010-11-30 2012-06-07 Novartis Ag Uses of anti-cd40 antibodies in combination therapy for b cell-related cancers
SG10202109925TA (en) 2013-02-14 2021-10-28 Univ Arkansas Compositions and methods of enhancing immune responses to eimeria or limiting eimeria infection
AU2014239557B2 (en) 2013-03-15 2019-01-03 The Board Of Trustees Of The University Of Arkansas Compositions and methods of enhancing immune responses to enteric pathogens
SG11201809686SA (en) 2016-05-03 2018-11-29 Univ Arkansas Yeast vaccine vector including immunostimulatory and antigenic polypeptides and methods of using the same
CA3044424C (en) * 2016-11-21 2023-05-23 Nant Holdings Ip, Llc Fractal combination therapy
WO2019241592A1 (en) * 2018-06-14 2019-12-19 Nantbio, Inc. Tnf-type receptor-ligand fusion proteins and methods
CN113056479A (en) * 2018-10-05 2021-06-29 南特细胞公司 CD40 and CD40L conjugates in an adenoviral vaccine vehicle

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993008207A1 (en) * 1991-10-25 1993-04-29 Immunex Corporation Novel cytokine
US5716805A (en) * 1991-10-25 1998-02-10 Immunex Corporation Methods of preparing soluble, oligomeric proteins
US7070771B1 (en) * 1996-12-09 2006-07-04 Regents Of The University Of California Methods of expressing chimeric mouse and human CD40 ligand in human CD40+ cells

Also Published As

Publication number Publication date
CA2369820A1 (en) 2000-10-26
AU3966200A (en) 2000-11-02
JP2003508016A (en) 2003-03-04
WO2000063395A1 (en) 2000-10-26
AR023482A1 (en) 2002-09-04
EP1173589A1 (en) 2002-01-23
NO20015003D0 (en) 2001-10-15
IL144952A0 (en) 2002-06-30

Similar Documents

Publication Publication Date Title
NO20015003D0 (en) Nucleic Acids Encoding CD40 / CD40L Chimeric Polypeptides, Methods of Preparation and Use thereof
ZA200110161B (en) Anti-avB3 recombinant human antibodies, nucleic acids encoding same and methods of use.
WO2003023008A8 (en) Therapeutic polypeptides, nucleic acids encoding same, and methods of use
AU2002221780A1 (en) Nucleic acids encoding cd40/cd40l chimeric polypeptides, methods for their production and uses thereof
AU9633301A (en) Paad domain-containing polypeptides, encoding nucleic acids, and methods of use
EP1487864A4 (en) Therapeutic polypeptides nucleic acids encoding same, and methods of use
AU2002356534A8 (en) Therapeutic polypeptides, nucleic acids encoding same, and methods of use
EP1446419A4 (en) Therapeutic polypeptides, nucleic acids encoding the same, and methods of use
EP1401858A4 (en) Therapeutic polypeptides, nucleic acids encoding same, and methods of use
EP1539985A4 (en) Therapeutic polypeptides, nucleic acids encoding same, and methods of use
EP1432726A4 (en) Therapeutic polypeptides, nucleic acids encoding same, and methods of use
AU2003217956A8 (en) Therapeutic polypeptides, nucleic acids encoding same and methods of use
AU2003247537A8 (en) Chd5 encoding nucleic acids, polypeptides, antibodies and methods of use thereof
EP1443913A4 (en) Therapeutic polypeptides, nucleic acids encoding same, and methods of use
EP1532238A4 (en) Therapeutic polypeptides, nucleic acids encoding same, and methods of use
AU2002365905A8 (en) Transaminases, nucleic acids encoding them and methods of making and using them
EP1399537A4 (en) Therapeutic polypeptides, nucleic acids encoding same and methods of use
AU2002365216A8 (en) Therapeutic polypeptides, nucleic acids encoding same, and methods of use
AU2003304034A8 (en) Therapeutic polypeptides, nucleic acids encoding same, and methods of use
WO2003060149A9 (en) Therapeutic polypeptides, nucleic acids encoding same, and methods of use
AU2003270424A8 (en) Therapeutic polypeptides, nucleic acids encoding same, and methods of use
EP1539807A4 (en) Therapeutic polypeptides, nucleic acids encoding same, and methods of use
EP1513864A4 (en) Therapeutic polypeptides, nucleic acids encoding same, and methods of use
AU2002360485A8 (en) Therapeutic polypeptides, nucleic acids encoding same, and methods of use
EP1504026A4 (en) Therapeutic polypeptides, nucleic acids encodings same, and methods of use

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application